| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 34,025 | 34,095 | 11.02. | |
| 33,950 | 34,295 | 11.02. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 150,00 | 57 | |||
| 60,00 | 15 | |||
| 51,76 | 50 | |||
| 46,800 | 1.030 | |||
| 45,000 | 401 | |||
| 44,000 | 300 | |||
| 42,000 | 300 | |||
| 36,700 | 40 | |||
| 32,985 | 36 | |||
| 32,765 | 235 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/0qf.htm [/URL] | ||||
| 235 | 32,705 | |||
| 138 | 32,605 | |||
| 36 | 32,470 | |||
| 6 | 32,355 | |||
| 500 | 31,000 | |||
| 100 | 30,000 | |||
| 100 | 28,400 | |||
| 120 | 20,800 | |||
| 300 | 20,000 | |||
| 1.052 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.587 | 0,952 | 2.464 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:35:48 | 32,360 | 148 |
| 17:29:56 | 32,260 | 360 |
| 17:28:55 | 32,350 | 971 |
| 17:26:40 | 32,215 | 145 |
| 17:26:40 | 32,210 | 120 |
| 17:26:40 | 32,200 | 137 |
| 17:25:44 | 32,175 | 15 |
| 17:22:40 | 32,125 | 171 |
| 17:20:05 | 32,160 | 13 |
| 17:17:22 | 31,970 | 87 |
| 17:17:14 | 31,970 | 700 |
| 17:13:16 | 31,810 | 100 |
| 17:13:16 | 31,805 | 26 |
| 17:08:27 | 31,670 | 100 |
| 17:07:34 | 31,660 | 63 |
| 17:06:50 | 31,675 | 279 |
| 17:06:47 | 31,660 | 168 |
| 17:06:00 | 31,630 | 132 |
| 17:00:06 | 31,745 | 1 |
| 17:00:06 | 31,745 | 3 |
| Tagesumsatz Xetra | -5,555 -14,65 % | 105.045 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Moderna Says FDA Refusal to Review mRNA Flu Vaccine Contradicts Federal Rules, Prior Guidance | 7 | MedCity News | ||
| Mi | After facing Moderna's ire, FDA stands behind decision to spurn mRNA flu filing | 8 | FierceBiotech | ||
| MODERNA Aktie jetzt für 0€ handeln | |||||
| Mi | Barclays Starts Moderna, Inc. (MRNA) Neutral as Biotech Outlook Improves | 12 | Insider Monkey | ||
| Mi | mRNA-Impfstoff: FDA lehnt Prüfung von Modernas Grippeimpfstoff ab | 9 | Pharmazeutische Zeitung | ||
| Mi | Mexico enlists Moderna to boost mRNA supply for respiratory diseases | 5 | Pharmaceutical Technology |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mi | Bio-Techne Corporation: Bio-Techne Announces Changes to its Leadership Team | PR Newswire | Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026
Steve Crouse, Senior Vice President... ► Artikel lesen | |
| Mi | Outlook Therapeutics, Inc.: Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter | GlobeNewswire (Europe) | ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of... ► Artikel lesen | |
| Mi | Biogen Inc.: Biogen Announces Board Chair Transition | GlobeNewswire (Europe) | Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new ChairCAMBRIDGE, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB)... ► Artikel lesen | |
| Mi | OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| Mi | EQS-DD: REPLOID Group AG: Addendum Invest FlexKapG, Verkauf | EQS Group (DE) | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
11.02.2026 / 18:35... ► Artikel lesen |